Jeffrey Mosebrook compensation by year
INTEGRA LIFESCIENCES Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $368,050 |
| Bonus | $111,888 |
| Stock awards | $760,156 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $13,200 |
| Total | $1,253,294 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INTEGRA LIFESCIENCES HOLDINGS CORP DEF 14A filed April 4, 2024, accession 0000917520-24-000053, and prior-year filings. Open the filing on EDGAR.
How this page was built: the INTEGRA LIFESCIENCES HOLDINGS CORP filed document, accession 0000917520-24-000053. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 16,695 | $727,067 | — |
| PSU | 3,659 | $159,349 | — |
| Option | 851 | — | $43.39 |
Per the Outstanding Equity Awards at Fiscal Year-End table in INTEGRA LIFESCIENCES HOLDINGS CORP's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
13 Form 4 lines since the FY2023 proxy (filed April 4, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-01 | Tax withholding | — | 937 | $17.89 | 34,516 |
| 2026-03-11 | Tax withholding | — | 806 | $9.61 | 35,453 |
| 2026-03-11 | Grant or award derivative | — | 15,957 | $0.00 | 15,957 |
| 2026-03-10 | Tax withholding | — | 341 | $9.55 | 36,259 |
| 2025-07-03 | Tax withholding | — | 3,345 | $13.49 | 36,600 |
| 2025-07-01 | Tax withholding | — | 937 | $13.25 | 39,945 |
| 2025-03-11 | Tax withholding | — | 134 | $23.95 | 35,677 |
| 2025-03-11 | Tax withholding | — | 309 | $23.95 | 35,368 |
The 8 most recent of 13 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
INTEGRA LIFESCIENCES’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Jan De Witte | President and Chief Executive Officer and Director | $6,388,756 |
| Michael McBreen | Executive Vice President, President, Codman Specialty Surgical | $2,830,152 |
| Lea Knight | Executive Vice President and Chief Financial Officer | $1,673,147 |
| Eric Schwartz | Executive Vice President, Chief Legal Officer & Secretary | $1,621,620 |
| Robert Davis | Executive Vice President, President, Tissue Technologies | $1,422,883 |
| Jeffrey Mosebrook · this page | Senior Vice President, Finance and Interim PFO | $1,253,294 |
| Carrie Anderson | Former Executive Vice President and Chief Financial Officer | $67,280 |
The full INTEGRA LIFESCIENCES compensation record
free company briefThis page is one person within INTEGRA LIFESCIENCES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the INTEGRA LIFESCIENCES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INTEGRA LIFESCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.